Aethlon Medical (DB:EJU0) - Stock Price, News & Analysis

EJU0 Stock Overview

A medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. More details

EJU0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€6M)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 4.5% per year for the next 3 years

+ 3 more risks

Aethlon Medical, Inc. Competitors

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€23.6m

aap Implantate

XTRA:AAQ1

€22.4m

NanoRepro

XTRA:NN6

€19.7m

Price History & Performance

Summary of all time highs, changes and price drops for Aethlon Medical
Historical stock prices
Current Share Price	US$0.34
52 Week High	US$1.95
52 Week Low	US$0.20
Beta	1.75
11 Month Change	1.82%
3 Month Change	-9.19%
1 Year Change	-78.04%
33 Year Change	-98.38%
5 Year Change	n/a
Change since IPO	-98.10%

Recent updates

Shareholder Returns

	EJU0	DE Medical Equipment	DE Market
7D	2.4%	2.8%	1.1%
1Y	-78.0%	-5.7%	7.2%

Return vs Industry: EJU0 underperformed the German Medical Equipment industry which returned -4.7% over the past year.

Return vs Market: EJU0 underperformed the German Market which returned 8.6% over the past year.

Price Volatility

Is EJU0's price volatile compared to industry and market?
EJU0 volatility
EJU0 Average Weekly Movement	17.8%
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: EJU0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: EJU0's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1984	14	Jim Frakes	www.aethlonmedical.com

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Aethlon Medical, Inc. Fundamentals Summary

How do Aethlon Medical's earnings and revenue compare to its market cap?
EJU0 fundamental statistics
Market cap	€5.22m
Earnings (TTM)	-€10.67m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is EJU0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EJU0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$11.27m
Earnings	-US$11.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.81
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did EJU0 perform over the long term?

See historical performance and comparison

EJU0 Stock Overview

Risk Analysis

Aethlon Medical, Inc. Competitors

DB:AUG

€6.9m

XTRA:GME

€23.6m

XTRA:AAQ1

€22.4m

XTRA:NN6

€19.7m

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Recent updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Insufficient new directors

Aethlon Medical, Inc. Announces Executive Changes

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Revenue beats expectations

New 90-day high: €2.30

Aethlon Medical, Inc. to Report Q3, 2021 Results on Feb 10, 2021

Aethlon Medical, Inc. Announces Executive Appointments

New 90-day high: €2.10

Aethlon Medical, Inc. Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

New 90-day high: €1.94

New 90-day high: €1.49

Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. Announces Executive Changes, Effective as of October 30, 2020